RAPID ALERT

DRAP ALERT No: I/S/02-25-20

CRACKDOWN AGAINST FALSIFIED/SPURIOUS DRUGS

Date: 20th February, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Pharmacies and medical stores

Problem Statement:

Drug Testing Laboratory, Sindh has notified the Drug Regulatory Authority of Pakistan that samples of following products, collected by various provincial drug inspectors, have been declared '***Spurious***' (falsified). The details of the reports are as below:

Sr#	Product name	Batch/Lot No.	Stated Manufacturer	Test Results
1.	Nuberol Forte Tablets (Paracetamol & Orphenadrine citrate)	DB0982	M/s Searle Company Limited, 32-Km Multan Road, Lahore	Spurious, Orphenadrine Citrate not identified.
2.	Phenobar Tablet (Phenobaritone)	QA 008	M/s Star Laboratories (Pvt) Ltd, 23-Km Multan Road, Lahore	Spurious, Phenobarbitone not identified.
3.	Iodex CMS Ointment (Methyl Salicylate)	HIAAC	M/s GSK Pakistan Limited, F/168, SITE, Karachi.	Spurious, Methyl Salicylate not identified.

Risk Statement:

Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.

DRAP, Islamabad **+ 92 051 9255969** **gsms@dra.gov.pk**

Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate the mentioned products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk